Investigational Drug Abaloparatide Reduces the Incidence of Fractures in Postmenopausal Women With Osteoporosis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ACN
3. NVDA
4. MU
5. GOOGL
6. APGE
7. ABBV
8. DFTX
9. USO
10. IBM

Go back to Investigational Drug Abaloparatide Reduces the Incidence of Fractures in Postmenopausal Women With Osteoporosis

Radius Health (RDUS) Trades to Session Lows

October 12, 2015 2:41 PM EDT

Radius Health (Nasdaq: RDUS) is moving to session lows Monday after the company announced the... More

Radius Health (RDUS) Presents Positive Top-Line Data from ACTIVExtend Phase 3 in Postmenopausal Osteoporosis

October 12, 2015 2:32 PM EDT

Radius Health (NASDAQ: RDUS) announced positive top-line data from the first six months of the ACTIVExtend trial that showed women who were previously treated with 18 months of abaloparatide (ABL) subcutaneous (SC) injection experienced no new vertebral fractures and an increased bone mineral density (BMD) during the first six months of treatment on alendronate (ALN). These data were presented today at a plenary oral session during the American Society for Bone and Mineral Research (ASBMR) 2015 Annual Meeting.

The first six months of the Phase 3 ACTIVExtend trial were conducted in 1,139 subjects enrolled in the ACTIVE... More